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The following includes commentaries on how genetic code of Barrett’s esophagus (BE) patients, the mechanisms
for GERD-induced esophageal expression of caudal homeobox, and the development of Barrett’s metaplasia are
increasingly better known, including the role of stromal genes in oncogenesis. Additional lessons have been learned
from in vitro models in nonneoplastic cell lines, yet there are limitations to what can be expected from BE-derived
cell lines. Other topics discussed include clonal diversity in Barrett’s esophagus; the application of peptide arrays
to clinical samples of metaplastic mucosa; proliferation and apoptosis of Barrett’s cell lines; tissue biomarkers for
neoplasia; and transcription factors associated with BE.
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Concise summaries
• The mechanisms for GERD-induced esopha-
geal expression of caudal homeobox and de-
velopment of Barrett’s metaplasia are better
known, as is the genetic code of Barrett’s pa-
tients, but there is not a specific genetic code
predictive of Barrett’s esophagus (BE). There
is an upregulation of embryological pathways
that are silenced in the late and postembryonic
phase; the role of stromal genes in oncogen-
esis, as shown in rat models, as well as the
lessons learned from in vitro models in non-
neoplastic cell lines are helpful to understand
the natural history of the disease. The clonal
diversity in BE must be emphasized, but there
are limitations to what can be expected from
BE-derived cell lines. In vitro experiments with
cells in culture should be viewed as prelimi-
nary, and will need to be confirmed by ex vivo
studies with whole Barrett’s tissues that include
elements of the stroma. Ultimately, in vivo lon-
gitudinal studies will need to confirm the path-
ways toneoplasia.Novel in vitromodels demon-
strate that benign Barrett’s epithelial cells can
change phenotype expression following expo-
sure to acid and bile. The study of proteomics
will probably result in an unparalleled under-
standing of BA carcinogenesis and will not only
be helpful in identifying BE patients at risk
for progression, but they will also be critical
in better defining tumor stage. The complete
transformation of normal esophageal squa-
mous cells into intestinal type cells might be
through a cooperative interactionofBMP-4 and
CDX-2.
doi: 10.1111/j.1749-6632.2011.06043.x
18 Ann. N.Y. Acad. Sci. 1232 (2011) 18–35 c⃝ 2011 New York Academy of Sciences.
Souza et al. Genetic and cell changes in Barrett’s patients
• In nondysplastic Barrett’s cells, acid expo-
sure decreases proliferation and causes a slight
increase in apoptosis. In contrast, bile salt ex-
posure does not induce apoptosis in ex vivo
cultures of nondysplastic Barrett’s cells. Levels
of the tumor suppressor and transcription fac-
tor are frequently increased with progression to
HGD and may be useful markers for adeno-
carcinoma, but this is a mutated form that is
transcriptionally inactive.
1. Is there a specific genetic code
predictive of BE to be considered as a
useful tool in epidemiologic studies?
Rhonda F. Souza
rhonda.souza@utsouthwestern.edu
BE develops through metaplasia, which is the pro-
cess whereby one adult cell type replaces another.
In the esophagus, the normal esophageal squamous
epithelium becomes replaced by specialized intesti-
nal epithelium that is characteristic of BE. In a gen-
eral Swedish population, the prevalence rate of BE
was found to be 1.6%.1 Data from the United States
suggest that familial Barrett’s accounts for 7.3% of
cases, whereas the vast majority of cases are consid-
ered sporadic.2
Familial Barrett’s esophagus
Familial BE is defined as having a first- or second-
degree relativewithBE, esophageal adenocarcinoma
(EAC), or adenocarcinoma of the gastresophageal
junction.2 Recent data generated from 881 “familial
Barrett’s” families suggest that there is inheritance
of one or more rare autosomal dominant suscepti-
bility alleles in these families.2 However, no specific
genetic code indicative of familial BE has been iden-
tified yet.
Sporadic Barrett’s esophagus
The main risk factors for BE are advanced age, male
gender, white ethnicity, obesity, and gastresophageal
refluxdisease (GERD).Of these risk factors, theones
that have been investigated for genetic variation as
a predictor of BE include GERD and obesity. GERD
is a major risk factor for BE.
So maybe rather than BE being an inherited con-
dition, perhaps GERD is the inherited condition
in these patients. In support of such a hypothe-
sis, a number of studies have found a clustering
of symptomatic GERD among relatives of patients
with BE, suggesting that in Barrett’s families there
may be a genetic component for GERD. However,
one study has also reported a clustering of symp-
tomatic GERD among relatives of GERD patients
without BE, which refutes this hypothesis.3
Regardless, no specific genetic code indicative
of familial GERD has been identified yet. Even if
there was an inherited predisposition to GERD, this
would still not explainwhyonly aminority ofGERD
patients develop BE. So perhaps there is another
mechanismwherebyGERD causes aminority of pa-
tients to develop BE. Gastresophageal reflux clearly
leads to reflux esophagitis. In a minority of GERD
patients, this inflammation can heal with the de-
velopment of Barrett’s metaplasia (BM). So it is
conceivable that genetic alterations in the reflux-
mediated inflammatory responsemaypredictwhich
GERD patients develop BE. In fact, there are a
number of studies suggesting that patients with BE
maybe genetically predisposed to more severe in-
flammation in response to reflux.4
Obesity is the other risk factor, which has been in-
vestigated for genetic variation as a predictor of BE.
Although it is not entirely clear exactly how obe-
sity contributes to the development of BE, one way
might be to increase GERD. Another way may be
to mediate signaling through the pro-proliferative
insulin and insulin-like growth factor pathways. In
fact, obese patients with BE may be genetically pre-
disposed to enhanced signaling via these pathways
by alterations in the IGF-1R. In one study, blood
from obese patients with and without BE was ana-
lyzed for the presence of a pro-proliferative IGF-1R
genotype.5 The investigators found that there was
no difference between obese patients with BE and
those without GERD or BE in the frequency of the
wild-type genotype for IGF-1R.5 In contrast, they
found that obese patients with BE were more likely
to have a pro-proliferative IGF-1R genotype than
obese patients without GERD or BE.5
Conclusion
Is there a specific genetic code predictive of BE to be
considered a useful tool in epidemiological studies?
The answer is NO.
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2. What is the role of developmental
signaling pathways in the mechanisms by
which GERD may induce the esophageal
expression of Caudal homeobox (Cdx)
genes that mediate the development
of BM?
Giancarlo Freschi, A. Taddei, M.N. Ringressi, V.
Ceccherini, F. Castiglione, D.R. Degl’Innocenti, and
P. Bechi
giancarlo.freschi@unifi.it
To determine the molecular mechanisms respon-
sible for BM, it is important to understand how
tissue types are specified during normal develop-
ment. A specific set of transcription factors, like
Hox genes or Cdx genes specifying intestine and
signaling molecules, are important regulators of
tissue type during embryogenesis.
Particularly CDX2, a homeobox gene, has a role
in the development of the gastrointestinal tract. In
fact, CDX2 has been shown to be an important
transcriptional regulator in maintenance of nor-
mal adult small intestine and colonic epithelium
and has been shown to activate other intestinal
differentiation genes, including MUC2.
Cdx genes in BE
CDX2 is not expressed in normal esophageal mu-
cosa but is abundantly re-expressed in intestinal
metaplastic mucosa in the esophagus, and im-
munohistochemical staining studieshave confirmed
that the CDX2 protein is overexpressed in hu-
man BM.6 Animal studies have suggested that gas-
tresophageal reflux may enhance CDX2 expres-
sion in rat esophageal keratinocytes and studies of
CDX2 gene expression in human esophageal biopsy
specimens reveal an increase at each step in the
development of BE.7
Although in vitro studies have demonstrated in-
creased CDX2 promoter activity, RNA and protein
expression, and upregulation of downstream tar-
get genes, Cdx regulation is an incompletely un-
derstood process, but it probably involves complex
interactions among key signaling pathways, mor-
phogenetic factors, and transcription factors in-
volved in regulating embryonic development and
in maintaining the homeostasis of adult tissues.
Literature suggests that many developmental sig-
naling pathways, like Wnt, BMP, transforming
growth factor-", hedgehog, notch, NF-!B, and
other growth factor pathways play an important role
in this process.8
Bone morphogenetic proteins (BMPs) are a
group of growth factors now considered to
constitute a group of pivotal morphogenetic
signals, orchestrating tissue architecture through-
out the body http://en.wikipedia.org/wiki/Bone
morphogenetic protein-cite note-1. They are an
important factor in the progression of colon
cancer and, conversely, overactivation of BMP
signaling following reflux-induced esophagitis
provokes BE and is thus instrumental in the de-
velopment of adenocarcinoma in the proximal por-
tion of the gastrointestinal tract. Supporting this
contention, recent studies suggest that GERD may
cause esophageal stromal cells to express BMP-4,
one of the key players in early morphogenesis of the
esophagus, which promotes the change from squa-
mous to columnar epithelium.
Notch
Notch is translocated to the nucleus where it inter-
acts with transcription factors to become a tran-
scriptional activator and then can modulate the
expression of Notch target genes that regulate cell
fate decisions. The hypothesis is that exposure of
esophageal cells to the bile acid, deoxycholic acid
(DCA), results in inhibition of the Notch pathway,
with alterations in its downstream effectors and in-
duction of CDX2 expression.
NF-κB
Recent evidence suggests that the transcription fac-
tor nuclear factor !B may be a candidate factor
linking inflammation to cancer because it plays
a central role in the inflammatory cascade and
has been linked to cancer development. NF-!B is
found at increasing levels from normal esophagus
to esophagitis and from BM to EAC. NF-!B has
been shown to be integral to the regulation of two
homeobox genes, caudal type homeobox transcrip-
tion factors (CDX) 1 and 2. There is now increasing
evidence of a link between NF-!B and the CDX
genes, suggesting a mechanism by which inflamma-
tion could induce metaplasia.9
Wnt
TheWnt-signaling pathway is essential inmany bio-
logical processes and numerous studies of this path-
way over the past years have led to the identifica-
tion of several novel components. CDX2 has been
shown to be a downstream target of WNT, and the
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Figure 1. Relative expression of pontin and reptin genes in BM with respect to normal esophageal mucosa.
cytoplasmic accumulation and nuclear transloca-
tion of "-catenin, a transcription factor, represents
a key step in the activation of the pro-oncogenic
canonical WNT pathway.
Here, in comparison to normal, GERD, or BM
tissues, "-catenin was found to be overexpressed
in about one-third of EA tissues. Of particular
interest were several significant associations be-
tween the expression of "-catenin and CDX2 in
esophageal tissues, suggesting a central role for the
WNT/CDX2 pathway in the molecular pathogene-
sis of EA. In the absence of the signal, action of the
destruction complex (CKI#, GSK3", APC, and
Axin) creates a hyperphosphorylated "-catenin,
which is a target for ubiquitination and degradation
by the proteosome. Binding of Wnt leads to sta-
bilization of hypophosphorylated "-catenin, which
interacts with TCF/LEF proteins in the nucleus to
activate transcription.10 "-catenin activity is further
modulated by other factors. Among these there is
pontin and reptin.
Pontin and reptin
Pontin (Ruvb1) and reptin (Ruvb2) are highly con-
served components of multimeric protein com-
plexes important for chromatin remodeling and
transcription. They interact with many different
proteins, including c-myc and "-catenin, and thus
potentially modulate different pathways. In other
words, pontin and reptin are Wnt-signaling inter-
action partners that antagonistically modulate "-
catenin transcriptional activity.
Personal data
From our previous analyses using real-time PCR
on rectal carcinoma samples, we observed that the
expression of pontin is clearly more prevalent than
that of reptin. We performed the same study on
BE samples, and the results were inconsistent for
pontin, whereas reptin expression appeared to be
more prevalent in the various BM samples (Fig. 1).
We have begun to check BM biopsies for the ex-
pression of other key transcription factors known
to effect intestinal differentiation, especially HOX
genes (HoxD locus in particular). Significant dif-
ferences exist for some of the genes, both in BM
compared to a normal esophagus and compared to
simple esophagitis (Fig. 2). This confirms our opin-
ion, as well as that of many other researchers, that
a single transcription factor like CDX2 is probably
Figure 2. Relative expression of HOXD8 and HOXD12 genes in BM with respect to normal esophageal mucosa.
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not solely responsible for a change as dramatic as
that of BE, and that the homeobox gene network
(HOX and CDX) acts just like an integrated circuit,
with yet unexplored potential.
Although these data are very interesting, they are
merely speculative and observational and obviously
needs to be backed up with functional correlations
with other types of experiments.
Conclusions
From recent findings, it has become apparent that
in BM there is upregulation of embryological path-
ways that are silenced in the late and postembryonic
phase. Identification of CDX2 as a key transcrip-
tional regulator, and studies dissecting its activa-
tion are rapidly evolving, as is our understanding of
its potential pathogenesis. The interaction of differ-
ent components (Wnts, BMPs, Shh) is required for
proper morphogenesis of the intestine but also for
cdx gene expression and thus for BM. Future inves-
tigation of these factors is fundamental to further
delineate the enigma of BM and to develop novel
molecular therapeutic strategies aimed at prevent-
ing or reversing this premalignant condition. These
additional studiesmay bewarranted in several areas,
especially how signaling pathways and transcription
factors (such as CDX1, CDX2, andHOXgenes)may
interact with each other tomediate the development
of BM (Fig. 1).
3. What model systems are likely to show
the impact of acid and bile on gene
expression of the esophagus in vivo?
George Triadafilopoulos
vagt@stanford.edu
Thus far there have been two settings in which re-
search has been done to address the question of acid
and bile on gene expression. The first setting has
been various cell culture systems, the latter, an ex
vivo tissue culture Barrett’s tissues, and both have
been extensively used.
In one of many examples using cell lines, and
to explore mechanisms whereby acid reflux might
contribute to carcinogenesis in BE, Souza et al.,
studied the effects of acid on the mitogen-activated
protein kinase (MAPK) pathways, cell proliferation,
and apoptosis in aBarrett’s adenocarcinoma cell line
(SEG-1).11 SEG-1 cells were exposed to acidicmedia
for threeminutes, and the activities of threeMAPKs
(ERK, p38, and JNK) were determined. Prolifera-
tion was assessed using flow cytometry; cell growth
and apoptosis were assessed using cell counts and
an apoptosis ELISA assay. They found that acid-
exposed SEG-1 cells exhibited a significant increase
in proliferation and total cell numbers, and a sig-
nificant decrease in apoptosis. These effects were
preceded by a rapid increase in the activities of ERK
and p38, and a delayed increase in JNK activity.
In a classic example of ex vivo experiments, and
because acid is a major component of refluxate,
Fitzgerald et al.12 investigated its effects ex vivo
on cell differentiation as determined by villin ex-
pression, and on cell proliferation, as determined
by tritiated thymidine incorporation and prolif-
erating cell nuclear antigen expression. To mimic
known physiological conditions, endoscopic biop-
sies of normal esophagus, BE, and duodenum were
exposed, in organ culture, to acidified media (pH
3–5) either continuously, or as a one hour pulse
and compared with exposure to pH 7.4 for up to 24
hours. Before culture, villin expression was noted
in 25% of metaplasia samples, and increased af-
ter 6 or 24 hours of continuous acid to 50% or
83% of metaplasia, respectively. Increased villin ex-
pression correlated with ultrastructural maturation
of the brush border. In contrast, an acid-pulse fol-
lowed by culture at pH 7.4, did not alter villin ex-
pression in BE.Moreover, continuous acid exposure
blocked cell proliferation in BE, whereas, an acid-
pulse enhanced cell proliferation, as compared to
pH 7.4. Based on their ex vivo findings, the au-
thors proposed a model in which the diverse pat-
terns of acid exposure in vivo might contribute to
the observed heterogeneity and unpredictable pro-
gression to neoplasia of BE. However, both these
types of models carry inherent limitations, and they
do not address acid and bile reflux on metaplasia in
vivo. One of their key limitations is the noninvolve-
ment of the stroma in such experiments, because
it plays an increasingly important role in Barrett’s
carcinogenesis.13
A small animal endoscopy in a rat model of BE
has been recently described and it appears promis-
ing in the in vivo study of gene expression in this
disease.14 The model allows the performance of
surveillance, classification of mucosal patterns, for
observation of the onset of intestinal metaplasia,
andmonitoring the progression of neoplastic trans-
formation. Advantages of the model include (1) the
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Figure 3. Esophageal histology at 36 weeks in an animal model of Barrett’s carcinogenesis that allows for dynamic assessment of
acid and bile exposure on gene expression in vivo.
esophago-gastro-jejunal anastomotic procedure is
easy to perform; (2) it allows reflux of both acid and
bile to occur and alter the biological behavior of BE;
(3) gastric function, weight, and nutritional status
are preserved; and (4) there is a high rate of animal
survival and ability to achieve rapid gain in body
weight. Figure 3 reveals esophageal histology at 36
weeks in the model.
Souza et al. also examined the ability of acid to
activate theMAPK pathways in vivo in patients with
BE.11 MAPK activation was studied in biopsy spec-
imens taken from patients with BE before and after
esophageal perfusion for three minutes with 0.1N
HCl. In these patient experiments, acid exposure
significantly activated the MAPK pathways in the
metaplastic epithelium.
The clonal evolution model in BE has recently
evolved.15 The concept of an initial single clone
that evolves and accumulates genetic defects, has
now been replaced by another model, in which
multiple defective clones progress independently or
together into malignant transformation. This lat-
ter model has been substantiated by recent ex vivo
studies by Leedham et al.,16 who aimed to assess
clonality at a much higher resolution by microdis-
secting and genetically analyzing individual crypts.
Determinationof tumor suppressor gene loss of het-
erozygosity patterns, p16 and p53 point mutations,
were carried out on a crypt-by-crypt basis. Cases
of contiguous neosquamous islands and colum-
nar metaplasia with esophageal squamous ducts
were identified. Tissues were isolated by laser cap-
ture microdissection and genetically analyzed. In-
dividual crypt dissection revealed mutation pat-
terns that were masked in whole biopsy anal-
ysis. Dissection across esophagectomy specimens
demonstrated marked clonal heterogeneity, with
multiple independent clones present. The authors
identified a p16 point mutation arising in the squa-
mous epithelium of the esophageal gland duct,
which was also present in a contiguous metaplas-
tic crypt, whereas neo squamous islands arising
from squamous ducts were wild-type with respect
to surrounding Barrett’s dysplasia. They concluded
that by studying clonality at the crypt level they
demonstrated that Barrett’s heterogeneity arises
from multiple independent clones, in contrast to
the selective sweep to fixation model of clonal ex-
pansion previously described. They also suggested
that the squamous gland ducts situated through-
out the esophagus are the source of a progenitor
cell that may be susceptible to genemutation result-
ing in conversion to Barrett’s metaplastic epithe-
lium. Additionally, these data suggested that wild-
type ducts might be the source of neo squamous
islands.
In conclusion, in vitro experiments with cells in
culture should be viewed as preliminary and will
need to be confirmed by ex vivo studies with whole
Barrett’s tissues that include elements of the stroma.
Ultimately, in vivo longitudinal studies will need to
confirm the pathways to neoplasia. Further, tissue
heterogeneity is common in Barrett’s epithelia and
reflects evolution of multiple mutated clones.
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4. What are the limitations of currently
available Barrett’s cell lines?
Jean S. Wang
jeanwang@wustl.edu
Cell lines serve as useful preclinical models of hu-
man disease and play an important role in research
on BE and EAC because of the limited availability
of patient samples and animal models. There are
currently ten authenticated EAC cell lines (FLO-
1, KYAE-1, SK-GT-4, OE19, OE33, JH-EsoAd1,
OACP4C, OACM5.1, ESO26, and ESO51) that have
been verified to be derived fromhuman EACs.17 Re-
cent technology using telomerase has now allowed
for the immortalization of Barrett’s cells. There are
currently three cell lines derived from patients with
BE and high-grade dysplasia and two cell lines de-
rived from patients with nondysplastic BE.18,19
One of themajor limitations of cell lines has been
contamination. It is estimated that up to one-third
of all cell lines have an origin other than what was
expected due to cross-contamination and mislabel-
ing of cultures. Recently, four commonly used EAC
cell lines were identified as being contaminated and
confirmed to be other tumor types.17 In fact, these
cell lines actually represented lung cancer, colorectal
cancer, gastric cancer, and esophageal squamous cell
carcinoma cell lines. Therefore, it is very important
to always authenticate cell lines by using DNA fin-
gerprinting techniques such as short tandem repeat
profiling or mutation analysis.
Another limitation is that we do not know how
similar or representative the cultured cells are com-
pared to the original cells. Barrett’s mucosa in vivo
is likely composed of a mosaic of different clonal
populations. Over time, clonal evolution and the
dynamics between thesemultiple clonesmay be im-
portant in the neoplastic progression to adenocarci-
noma.20 However, with a cell line, it is not possible
to evaluate the interaction between multiple clones.
Furthermore, artificial selection pressure during
the creation of the cell line may result in the propa-
gation of rare clones that have adapted successfully
to the cell culture conditions, and it is possible that
these clonesmaynot be representative of the biology
of the original esophageal tissue. The immortaliza-
tion procedures alone may affect the growth behav-
ior of cells. In addition, during the creation and
propagation of the cell line, there may be ex vivo
acquisition of genetic or epigenetic alterations.
Finally, another limitation with cell lines is that
it is difficult to replicate the natural in vivo envi-
ronment. BE is thought to develop through a mul-
tifactorial process that involves not only genetic
and epigenetic factors, but also interactions between
other important contributors in the microenviron-
ment suchas chronic inflammationand the complex
physiology behind acid and bile reflux in conjunc-
tionwith esophageal dysmotility. It is alsodifficult to
simulate the impact of various lifestyle factors such
as obesity, diet, and smoking, which may interact
and contribute to the development of BE or EAC.
Other unknown factors not yet discovered within
the microenvironment may also interact with the
Barrett’s cells and evaluating cell lines alone would
not allow for the study of these interactions.
To overcome some of the disadvantages of stan-
dard monolayer cell cultures, recently there has
been the development of innovative 3D culture
systems. These systems are multilayered structures
which mimic the tissue microenvironment by using
a monolayer of epithelial cells overlaid on a special
ECM gel enriched with collagen and fibroblasts.21
These models allow for the assessment of tumor
cell interaction with stromal components and are
a promising new technology that may help to over-
come some of the limitations seenwith standard cell
lines.
5. How is clonal diversity in BE
recognized?
Andrew C. Chang
andrwchg@umich.edu
While a number ofmolecular events have been iden-
tified in the neoplastic progression from BM to dys-
plasia and thence adenocarcinoma, the cellular ori-
gin of BM, as well as the mechanisms that drive
the development of tumor heterogeneity, remain a
matter of considerable debate. Clarification of the
extent of clonal diversity that exists within dysplas-
tic or malignant Barrett’s epitheliummight provide
further insight into these questions.
Tumor genetic heterogeneity may arise from the
development of genetic instability, which can lead to
alterations that confer an advantage in terms of sur-
vival or proliferation.While clonal diversity appears
to correlate with genetic instability, such diversity is
not equivalent to genetic instability but, instead, is
“a function of both the generation and selection
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of mutations.”22 Assessment of clonal diversity at
different stages of tumorigenesis can provide an in-
dication of the origins of tumor heterogeneity.23
Premises for the development of tumor hetero-
geneity include the cancer stem cell hypothesis and
clonal evolution.23 In the cancer stemcell hypothesis
pluripotent epithelial stem cells differentiate into ei-
ther squamous or intestinal-type columnar epithe-
lium, depending on the exposure to local stresses
such as gastresophageal refluxate.24 If there is more
than one progenitor cell population, tumor het-
erogeneity may develop as a result of ongoing and
diverging cellular proliferation and differentiation.
In the process of clonal evolution,25 malignancy
arises in a population of cells as a result of pro-
gressive accumulated genetic changes. Such changes
can confer either an advantage or disadvantage in
terms of survival or proliferation during natural se-
lection.23
Although tumor heterogeneity has been evalu-
ated widely in terms of specific genetic events or
histologic descriptors, in 2006, Maley et al. quan-
tified the clonal diversity of esophageal biopsies
obtained from patients with BE using methods of
molecular evolutionary biology.26 Using systematic
sampling across segments of BE, tissue biopsies
from 268 subjects were analyzed for DNA content,
changes in microsatellite length (shifts), and/or loss
of heterozygosity (LOH) at 9p and CDKN2A or
TP53 sequence mutations. In addition to segment
length and number of clones, diversity was mea-
sured by mean pairwise divergence, defined as the
number of loci showing molecular differences (e.g.,
LOH) divided by the number of informative (nor-
mal heterozygote) loci, or by the Shannon diversity
index to integrate the number and abundance of
clones.26 During mean follow-up of 4.4 years, EAC
developed in 37 subjects.
A number of diversity measures were predictive
for the development of EAC, particularly the num-
ber of clones (RR 1.40, 95% CI 1.13–1.73), mean
pairwise divergence (RR 1.45, 95% CI 1.08–1.95),
and Shannon index (RR 3.10, 95%CI 1.37–7.01), as
determined by 9p LOH, correcting for TP53 LOH
and abnormal DNA content. In multivariate anal-
ysis, the best predictive model for the development
of adenocarcinoma included mean pairwise diver-
gence and the number of clones.
To explore this further, this research group
demonstrated that increasing clonal diversity, as de-
termined by several other diversity measures, was
associated with increased risk for developing EAC.
In particular, they found that diversity found even
at evolutionarily neutral loci, specifically 9q and
17q, was as strongly associated with progression to
adenocarcinoma as at loci where genetic alterations
might confer a selective advantage, suggesting that
clonal diversity alone can be predictive for the pro-
gression to adenocarcinoma regardless of the un-
derlying molecular defect.22
Merlo et al. caution that novel but low abun-
dance “minority clones” might not be readily de-
tectable when utilizing tissue biopsies to determine
clonal diversity.22 Leedham et al. suggest that precise
compartmental localization (i.e., laser-capture mi-
crodissection) canbeused to evaluatemoreprecisely
the clonal nature of individual crypts.27 This group
observed considerable crypt-to-crypt clonal hetero-
geneity that otherwisemight be obscuredby analysis
of whole biopsy samples. Their findings lend further
credence to the concept that BE may develop as a
result of a number of molecular events occurring in
parallel, rather than being due to progressive step-
wise accumulation of genetic heterogeneity.
While the steps that lead to the development of
tumorheterogeneity and clonal diversity remainob-
scure, further elucidation of these mechanisms for
the pathogenesis of Barrett’s-associated adenocarci-
noma could directmore specific antineoplastic ther-
apy and improved clinical management.
6. How can the clonality study by
individual crypt dissection demonstrate
that Barrett’s epithelium heterogeneity
results from multiple individual clones?
Hugh Barr
hugh.barr@glos.nhs.uk
Despite years of active research, the histiogenesis
of BE, a metaplastic condition of the lower esopha-
gus, remains essentially unknown.Overmany years,
hypotheses have been generated and explored. One
area of direct interest are the esophageal gland ducts.
These are lined in the proximal two-thirds by a
cuboidal epithelium, and undergo a transition to
a stratified squamous epithelium as they approach
the lumen. It has been suggested that pluripoten-
tial stem cells may be located distally in the duct.
These become exposed, inflamed with ulceration,
and then heal with selective differentiation into an
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Figure 4. An endoscopic picture of multifocal high-grade
dysplasia in Barrett’s esophagus.
acid-resistant columnar phenotype. They then mi-
grate to the surface replacing the squamous lining.
This is similar to Wright’s “ulcer-associated cell lin-
eage” (UACL), a glandular differentiation occurring
at sites of intestinal ulceration.28
In addition, there is yet to be a consensus on the
the clonal evolution, clonal interaction, and neo-
plastic degeneration, and these subjects remain very
controversial issues. It may be that neoplasia devel-
ops through clonal selection which sweeps through
the Barrett’s segment.29,30 Nevertheless, BE is an
excellent area to examine and develop models and
systems to examine the progression to cancer. How-
ever, much of the work has been based on large
biopsy samples—heterogeneous samples taken at
multiple segments (Fig. 4).
Recently, Leedham et al.31 have contributed to
the histiogenesis debate by examining in detail in-
dividual crypts for genetic changes. The specimens
were obtained fromendoscopic resection specimens
and whole esophageal resection specimens from
endoscopic resection and esophagectomy speci-
mens. The Figure shows an endoscopic picture of
multifocal high-grade dysplasia. Individual laser
capturemicro-dissectionwas performed and tumor
suppressor genes, loss of heterozygosity, p16 and
p53 point mutations were examined on individual
crypts within these resected specimen. In addition
they examined neosquamous islands and metapla-
sia within the esophageal gland ducts. They clearly
identified mutation patterns that had been hidden
in whole biopsy analysis.
Clonal heterogeneity was identified, and p16mu-
tations were seen in the esophageal gland duct and
its associated metaplastic crypt. It appears that BE
may arise from multiple independent clones and is
very heterogeneous.
They also suggested that squamous gland ducts
could be the source of the metaplastic cells. This
confirms earlier morphological three dimensional
histological studies that have found continuity be-
tween human esophageal gland ducts and Barrett’s
mucosa. There was a gradual transition of the mor-
phological features of the cells lining the duct: nor-
mal cuboidal cells, lining the basal aspect of the duct,
intometaplastic cells as the duct opens onto themu-
cosal surface. This previously demonstrated a def-
inite interrelationship between the two structures.
However, identifying the direction of migration is
difficult.32
7. What lessons can be learned from the
influence of environmental factors on
various in vitro models and the cellular
phenotype(s) of the nonneoplastic
Barrett’s cell line about pathogenesis of
Barrett’s epithelium and its progression to
neoplasia?
Manisha Bajpai and K.M. Das
bajpaima@umdnj.edu
Epidemiology indicates a strong relationship be-
tween gastroesophageal reflux disease (GERD) and
EAC. Barrett’s epithelium is an intestinal type of
columnar metaplasia that replaces normal squa-
mous epithelium of the distal esophagus secondary
to chronic GERD.
Barrett’s epithelium is a major risk factor for de-
velopment of EAC, causing a 30–125-fold increased
risk in GERD patients complicated with BE. In BE,
suchmorphologic changes can be recognized with a
spectrum by pathologists as metaplasia–dysplasia–
adenocarcinoma (MDA).The esophageal squamous
epithelium is exposed to a dynamic environment
where the differentiation process is modulated by
the gastro-duodenal refluxate and GERD.
Various in vitro (nonneoplastic Barrett’s cell
lines, Barrett’s adenocarcinoma cell lines, normal
human esophageal epithelial cells, and in vivo
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Figure 5. Effect of continued treatment of BAR-T cells with acid and/or bile salt on colonic phenotype expression.
[rodent]) models have been used for the study of
pathogenesis of Barrett’s epithelium to columnar
metaplasia. Acid and assorted components of bile
have been implicated in the process of metaplasia of
native esophageal squamous epithelium.Presenceof
pluripotent stem cells, induction of NF-!B, CDX-2
(caudal homeo-box gene) expression, villin expres-
sion, and mucin-secreting cells, all favor the resem-
blance of metaplastic Barrett’s epithelium to intesti-
nal epithelium.However, there is limited knowledge
regarding the cellularphenotype(s) of thismetaplas-
tic process.
We utilized a nonneoplastic, telomerase-
immortalized Barrett’s cell line (BAR-T) that has
key histochemical features of benign Barrett’s ep-
ithelium.33 With intact p53 and p21 cell cycle check-
points, this cell line is ideal for studies on morpho-
logic, phenotypic, andmolecular changes under the
influence of environmental factors such as acid and
bile.
It is a heterogeneous cell line positive for CK4 a
marker for squamous, CK 8/18, mAb Das-1, villin,
and mucin, all markers indicative of intestinal type
of epithelium. Monoclonal antibody Das-1 is a
specific marker for colonic epithelium and incom-
plete type of gastricintestinalmetaplasia, type II and
III34, and it does not react with small intestinal ente-
rocytes and complete type or type I (intestinalmeta-
plaisa). However mAb Das-1 reacts with Barrett’s
epithelium with almost 100% sensitivity and speci-
ficity suggesting that Barrett’s epithelium is colonic
phenotype of metaplasia.35
We observed an increase in the columnar, and
particularly colonic phenotype (mAbDas-1 posi-
tive) cells (Fig. 5),36 when BAR-T cells were exposed
to acid and/or bile (glycocheno-deoxycholic acid,
GCDA 200$M) individually or in combination at
different pH, particularly at pH4, for five minutes
each day for up to three weeks. The CK4 phenotype
did not change.36
We hypothesized that prolonged, repeated expo-
sure of BAR-T cells to A + B may further induce
intestinal phenotype and lead to tumorigenicity. In
a systematic, prospective analysis over the course of
65 weeks, we demonstrated that following daily ex-
posure toA+B for a brief period of fiveminutes per
day, BAR-T cells showedprogressivemorphological,
molecular, and biological changes.
Morphological changes between untreated and
A+ B treated cells were evident from 34 weeks. The
treated cells grew as round or oval cells in clumps
and displayed acini-like formation (Fig. 6B). Un-
treated cells remained spindle shaped and evenly
dispersed on the culture plate (Fig. 6A). Changes in
p53 expression as well as p53 target genes, MDM2,
PERP, and p21, were consistent with a transformed
phenotype. Loss of anchorage dependence was ob-
served around 54 weeks of A + B treatment. The
A + B treated cells could form foci after overcon-
fluent on culture dishes (Figs. 6C and D), grow on
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Figure 6. Progressive tumorigenic changes in BAR-T cells upon chronic exposure to A+ B.
soft agar (Figs. 6E and F), and form tumors in nude
mice.37
Conclusion
The novel in vitro model demonstrates that benign
Barrett’s epithelial cells can change phenotype ex-
pression following exposure to acid and bile. This
phenotype change occurs in favor of columnar phe-
notype and particularly colonic (incomplete-type)
of metaplasia in BAR-T cells similar to in vivo sit-
uation3. This in vitro model further demonstrates
that continued exposure to acid and bile for longer
duration may cause transformation of benign Bar-
rett’s epithelium to neoplasia.37 BAR-T cells seem
to closely reproduce the pathophysiologic progres-
sion of Barrett’s epithelium and thus can be uti-
lized as an “in vitro” model to study the phenotypic
and molecular changes in the pathogenesis of Bar-
rett’s epithelium /EAC, to evaluate gene targets and
chemo-therapeutic candidates for treatment of Bar-
rett’s epithelium and to impede its progression to
EAC.
8. What insight into the molecular process
of Barrett’s esophagus can be expected by
applying peptide arrays to clinical samples
of metaplastic mucosa?
Georg Lurje, P. Kambakamba, C. Soll, M. Bueter,
and P.M. Schneider
paul.schneider@usz.ch
BE development is a multistep process that starts
with the mucosal injury of the squamous epithe-
lium of the distal esophagus by gastroesophageal
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reflux disease (GERD) and progresses through in-
testinalmetaplasia anddysplasia to invasiveBarrett’s
adenocarcinoma (BA). Approximately 10% of pa-
tients diagnosed with BE ultimately progress from
metaplasia to dysplasia and subsequently to BA.
Routine endoscopic surveillance of patients with BE
is an expensive practice due to the low rate of pro-
gression to EAC in patients without dysplasia. Iden-
tification of factors predicting progression to EAC
would substantially help to improve screening and
surveillance programs especially for patients with
BE without dysplasia. While most efforts have been
directed at genetic and epigenetic changes within
the MDA sequence, little is known about the pro-
tein changes that occur in the progression of the
disease.
Genomic-based approaches to biomarker devel-
opment include the measurements of expression
of full sets of mRNA and genomic DNA, such as
serial analysis of gene expression (SAGE) levels,38
large-scale gene expression arrays,39 and genomic
polymorphisms.40 As proteins are often subject to
proteolytic cleavage or posttranslational modifica-
tions, such as phosphorylation or glycosylation,
studies of differential mRNA expression are infor-
mative, but do not necessarily correlate with asso-
ciated protein expression or activity within a given
cell. Even though several potential biomarkers have
been described over the last decades, none of them
have been validated in a population based-study.
It is becoming increasingly apparent that dis-
ease progression is largely driven by complex
pathways, and analysis of one single genetic or
protein marker is unlikely to precisely predict pro-
gression of disease with sufficient resolution and re-
producibility. The human proteome—like the pro-
teomes of all organisms—is dynamic, changing
constantly in response to the needs of the body and
differs widely between people depending on fac-
tors such as age, gender, diet, level of exercise, and
sleep cycle. The proteome also changes in response
to cancer and other nonmalignant diseases, making
the proteome of great interest to cancer researchers.
The science of proteomics—the study of the totality
of proteins within a given cell, tissue, or oganism—
may therefore provide novel insights for the next
level of molecular inquiry that is represented by
functional genomics and proteomics.
Two-dimensional gel electrophoresis has been the
mainstay of electrophoretic technology for a decade
and is a commonly used tool for separating proteins.
In many cases, two-dimensional gel electrophoresis
evaluates whole-cell or tissue protein extracts. The
use of narrow, immobilized pH gradients for the
first dimension has increased resolving power for
the detection of low-abundance proteins. Radioac-
tive or fluorescent labeling and silver staining allows
visualization of hundreds of proteins in a single gel.
Over the past decade, advances in mass spec-
trometry (MS) and bioinformatics have improved
our ability to discriminate cancer-specific pep-
tides. As such, an MS-enhanced, high-resolution,
two-dimensional (2D), polyacrylamide gel elec-
trophoresis approach has been applied to further
improve detection and separation of proteins at a
wide range of pH gradientsmaximizing the number
of separated proteins to up to 2000 proteins using
a matrix-assisted laser desorption/ionization, time-
of-flight and tandem mass spectrometry (MALDI
TOF MS) technology.
Utilizing this technology, a recent study by Peng
et al. identified protein upregulation of ErbB3, Dr5,
cyclin D1, as well as several members of the zinc
finger protein family, in eight BAs and four nor-
mal mucosal control samples.41 Interestingly, these
proteins were validated in an independent set of
39 BA tissue samples by reverse-transcriptase PCR
(RT-PCR) and immunohistochemistry (IHC), sug-
gesting a critical role of these proteins in BA car-
cinogenesis.41 Another recent study by De Godoy
and coworkers, used advanced computational pro-
teomics to compare essentially all endogeneous
proteins in haploid yeast cells to their diploid
counterparts, suggesting that system-wide, precise
quantification directly at the protein level will help
to open new perspectives in postgenomics and
system biology.42 Although standards need to be
agreed upon for what determines the validity of
a biomarker, now that the draft of the human
genome has been completed, the field of proteomics
is emerging to tackle vast protein networks that both
control, and are controlled by, the information en-
coded by the genome.
The study of proteomics will probably result in
an unparalleled understanding of BA carcinogene-
sis and will not only be helpful in identifying BE
patients at risk for progression, but will also be
critical in better defining tumor stage, identifying
novel therapeutic targets, and measuring response
to therapy, thus tailoring a targeted and effective
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therapy to the molecular profile of both the patient
and the tumor while minimizing and avoiding life-
threatening toxicity.
9. Can active cell-signaling pathways in BE
be delineated?
Kausilia K. Krishnadath and F. Milano
k.k.krishnadath@amc.uva.nl
Several research groups have been performing stud-
ies to elucidate the role of CDX-2, a key intesti-
nal transcription factor involved in both physio-
logical and aberrant processes, such as intestinal
metaplasia, in BE. One relevant study was recently
performed by H. Kazumori and others, where it
was demonstrated that administration of bile and
acids to esophageal squamous cell lines increases the
CDX-2 gene transcriptional activity. In this study
they found, as well as in a rat surgical model, that
expression of CDX-2 andmucin-2, a direct target of
CDX-2, is increased upon bile and acid injury. They
hypothesized that this increased transcriptional ac-
tivity is mediated by NF-!B.43 In a study last year,
the group of R. Souza et al. confirmed these finding
esophageal primary cultures of BE patients.44
A few years after the 2006 study, the group of
Kazumori et al.performed another studywhere they
observed that CDX-1, belonging to the same family
ofCDX-2 transcription factors, is expressed in a sur-
gical ratmodel. Bile and acid exposure of esophageal
cell lines and rat esophageal primary keratinocytes
increased the promoter activity of CDX-1 transcrip-
tion factor, and overexpression of CDX-1 inHET1A
esophageal squamous cell line induced expressionof
mucin-2, an intestinal specific marker. The conclu-
sion from this study was that CDX-1 and CDX-2,
in the case of bile and acid injury in the esophageal
wall, autoregulate themselves and interregulate each
other.45
In 2008, Stairs and colleagues published inter-
esting data in the journal PloS One, where they
showed that EPC2-hTERT normal esophageal ker-
atinocytes, after transfection with c-myc and CDX-
1, show upregulation of mucin 5A, another pivotal
BEmarker, and of intestinal metaplasias, in a subset
of cells. Moreover, clonal gene expression of several
markers of BE, such as CDX-1, CDX-2, mucin2,
mucin 5a, and CK20, is observed after microarray
performed on patient material.46 In none of these
studies, however, was it demonstrated which mech-
anism determines exactly the development of an
intestinal phenotype.
Interestingly, D. Wang and others published im-
portant data about the involvement of the hedge-
hog pathway in the development of BM. Namely,
they looked at the expression of this pathway by
microarray in BE and found expression of sonic
hedgehog (SHH), namely. In functional studies,
they observed that treatment of HET1A cells with
BMP-4 induces expression of SOX-9, a transcrip-
tion factor found in paneth cells and stem cells of
the intestinal crypt. SOX-9, in turn, can upregu-
late expression of deleted in malignant brain tu-
mors 1 (DMBT1), an extracellular matrix protein
sufficient to induce a columnar-like phenotype in
mice. They concluded the study with the hypothe-
sis that bile and acid injury in the esophageal wall
determines the upregulation of aberrant SHH ex-
pression, which, in turn, upregulate BMP-4, and
subsequently SOX-9.47 However, once more, it was
not possible to observe the development of a spe-
cialized type of intestinal epithelium, as seen in
BE.
In 2005, in a study performed by our group, we
used SAGE and found that BMP-4 is uniquely ex-
pressed in BE as compared to squamous epithe-
lium.48 Here, we performed another study, whose
results were published in 2007. We found that
exposure of primary esophageal keratinocytes to
BMP-4 induces upregulation of pSMAD 1, 5, 8,
a downstream target of BMP-4, and by carrying
out microarray on these cells, we could observe
a shift of the gene expression pattern of the nor-
mal esophageal cells toward that of BE cells. At
the protein level, we observed that a switch of cy-
tokeratins expression pattern, toward those specif-
ically expressed in BE columnar cells, could be
achieved. However, we could not observe upregula-
tion of intestinal specific genes, such as mucin 2 and
villin 1.49
The concluding hypothesis of this study was that
BMP-4 is needed to initiate the transformation of
the normal esophageal cells into columnar cells, but
it is not sufficient to determine an entire shift of the
cells into an intestinal phenotype. Presently, we are
working on further defining these mechanisms, and
we hypothesize that the complete transformation
of normal esophageal squamous cells into intestinal
type of cells might be through a cooperative inter-
action of BMP-4 and CDX-2.
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10. What characteristics of Barrett’s cell
lines are related to proliferation and
apoptosis?
Rhonda F. Souza
rhonda.souza@utsouthwestern.edu
Traditional models that have been used to study
proliferation and apoptosis in BE include human
adenocarcinoma cell lines grown in culture, and
human esophageal biopsy specimens grown in ex
vivo organ culture. However, neither of these mod-
els is ideal for studying proliferation and apoptosis
in benign Barrett’s epithelial cells. Human adeno-
carcinoma cells have sustained numerous poorly
characterized genetic abnormalities, and they are
cancer cells, which have altered rates of proliferation
andapoptosis.Humanesophageal biopsies grown ex
vivo contain diverse and uncharacterized cell types,
so they are not useful for studies to address prolif-
eration or apoptosis specifically in Barrett’s epithe-
lial cells. To improve upon the traditional models
of BE, we and others have established telomerase-
immortalized nondysplastic Barrett’s epithelial cell
lines from endoscopic biopsy specimens from
patients with BE.50 These cells are immortalized by
telomerase expression but are not transformed.50
Characteristics of proliferation in Barrett’s cells
Proliferation of Barrett’s epithelial cells has been
studied in response to acid exposure using cultures
of Barrett’s-associated adenocarcinoma cells and
Barrett’s esophageal biopsies. In these in vitromod-
els, acid exposure has been shown to increase prolif-
eration.51,52 However, using nondysplastic Barrett’s
epithelial cells (BAR-T), we have reported very dif-
ferent effects of acid on proliferation. Cell number
was significantly decreased by a 10-min exposure to
acid in three Barrett’s epithelial cell lines.53 Using
flow cytometry, we determined the effects of acid
specifically on cell proliferation. At two hours fol-
lowing a 10-min exposure to acid, we found that
there were slightly more cells in G1 and significantly
less cells in S phase in the acid treated group com-
pared to controls.4 By four hours, we found signif-
icantly more cells in G1 and significantly less cells
in S phase in the acid treated group compared to
control suggesting that acid decreases proliferation
by causing a delay in cell cycle progression at the
G1-S cell cycle checkpoint.53 Subsequent data from
our laboratory have demonstrated that acid caused
DNA double strand breaks due to generation of in-
tracellular reactive oxygen species suggesting that
the antiproliferative effects of acid are in response
to genetic damage.
Characteristics of apoptosis in Barrett’s cells
We have also reported that a 10-minute exposure
to acid induces a small (1%), but statistically sig-
nificant increase in apoptosis in Barrett’s epithelial
cells.53 Apoptosis of Barrett’s epithelial cells has also
been studied in response to bile acid exposure us-
ing ex vivo cultures of esophageal squamous and
Barrett’s esophageal biopsies.54 In these models, ex-
posure to the unconjugated bile acid DCA increased
apoptosis in the esophageal squamous biopsies, but
not in the BE biopsies, suggests that the Barrett’s ep-
ithelial cells resist apoptosis in response to bile acid
exposure.54
Conclusions
In nondysplastic Barrett’s cells, acid exposure de-
creases proliferation and causes a slight increase in
apoptosis. In contrast, bile salt exposure does not in-
duce apoptosis in ex vivo cultures of nondysplastic
Barrett’s cells.
11. Are there tissue biomarkers that can
stratify risk for future neoplasia in BE?
Usha Malhotra, A. Atasoy, A. Zaidi, K. Nason, B.A.
Jobe, and M. Gibson
malhotrau@upmc.edu
BE is one of the most significant known risk factors
for development of EAC. The proportion of patients
with BE progressing to EAC is small, thus there are
continuous efforts to stratify these patients accu-
rately to focus rigorous surveillance on a high risk
group in a cost effective manner. Clearly, the avail-
able clinical and endoscopic criteria are not highly
predictive and this has led to increasing interest
in biomarkers. Early Detection Research Network
(EDRN)hasproposedfivephases of biomarker eval-
uation 55 as illustrated in Table 1. Various biomark-
ers have been studied in context of Barrett’s progres-
sion and are in different phases of development.
DNA content abnormalities
(aneuploidy/tetraploidy)
Multiple studies have evaluated DNA content ab-
normalities due to structural and or numerical
changes in chromosomenumbers. They have shown
Ann. N.Y. Acad. Sci. 1232 (2011) 18–35 c⃝ 2011 New York Academy of Sciences. 31
Genetic and cell changes in Barrett’s patients Souza et al.
Table 1.Phases of biomarker development
1 Identification
2 Cross-sectional studies for validation and
standardization of assay
3 Case-control studies to confirm expression
4 Prospective longitudinal studies
5 Population-based studies
variable relative risk of progression with one phase
4 study showing a five year cumulative cancer rate
of 28%.56 DNA content abnormalities are one of
the most widely studied markers of progression in
subjects with BE, but technical challenges with flow
cytometry, in addition to need for specialmedia, has
limited widespread application.
Tumor suppressor loci abnormalities
p53, a well-known tumor suppressor, has been
shown to be frequently inactivated in Barrett’s car-
cinoma progression. There is convincing evidence
that supports p53 LOHas a fairly accurate predictive
marker. 57 Evaluation of p53 LOH requires genotyp-
ing that is currently limited to the research setting.
Immunohistochemistry has been proposed to be an
alternative means of evaluation but is not as accu-
rate. Thus, despite high predictive power, clinical
use has been a challenge.
p16 hypermethylation
Epigenetic silencing of p16 is one of the most com-
mon abnormalities reported in BE. Its high preva-
lence has led to its evaluation inmultiple studies, but
predictive power has been found to be low.58 It has
been proposed that this may be the initial event cre-
ating an environment conducive for further accu-
mulation of genetic changes and eventually leading
to the progression to carcinoma.
Other biomarkers of interest
Cyclin D1, aberrant methylation of tumor suppres-
sor genes: RUNX3 and HPP1, HEr2/Neu, c-myc,
COX2, EGFR, survivin, caspase 3, and E-cadherin.
To address the initial question, there are tissue
biomarkers that may help in risk stratification, but
none of them are equipped for widespread clinical
use.
Future directions
With increasing availability of compelling infor-
mation on various biomarkers, there has been an
interest in evaluation of panels combining clin-
ical features, endoscopic criteria, and molecular
biomarkers as tools of risk stratification.
12. Is there one transcription factor that
shows a significant increase in the
progression from BM to adenocarcinoma?
John P. Lynch
lynchj@mail.med.upenn.edu
The basis for this question likely emerges fromwhat
is currently understood or suspected regarding the
pathogenesis of BE.59 Presently, one model for BE
holds that ectopic expression of transcription fac-
tors and growth factors normally associatedwith the
intestine and colon contributes to the emergence of
the intestinal metaplasia. A number of transcrip-
tion factors have been identified with prominent
roles in BE pathogenesis including C, Gli (SHH),
Smad (BMP4), Sox9, and NF-!B. The criteria by
which these factors were identified include (1) they
are not normally expressed in the esophagus; (2)
they are nearly universally detected in BE tissues;
(3) they have prominent roles in intestinal devel-
opment or cellular responses to inflammation; and
(4) for many of these factors there is experimental
data from cell culture and animal models demon-
strating their contribution to promoting intestinal
metaplasia.59
The question is, then, can we identify a tran-
scription factor or factors that meet similar criteria
and that are equally important for transforming BE
cells into neoplastic adenocarcinoma cells? A re-
view of the literature finds a number of microar-
ray and other genetic studies of EACs that have
identified candidate factors. Most of these stud-
ies compared gene expression patterns in BE tis-
sues and EACs, and suggested increased expression
of Sox9, ERG3, ERG4, c-Myc, COX2, DNMT3b,
RARa, SPARC, and Wnt/"-catenin are all asso-
ciated with progression from BE to EAC.60 One
problem with these candidates is that all are ex-
pressed in BE without dysplasia, only their levels are
increased with progression to cancer. This seems
unsatisfactory, since none would appear to have the
same dramatic transforming effect as those factors
associated with BE pathogenesis; none are presently
being utilized as a marker predicting disease
progression.
However, one transcription factor does meet
these stringent criteria in an unexpected way, and
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Figure 7. Functions of the tumor suppressor and transcription factor p53. The p53 gene targets are indicated with their associated
tumor-suppressor functions.
that factor is p53. p53 is a transcription factor
and a well-known tumor suppressor. The genes
targeted by p53 perform many tumor–suppressor
functions, including growth arrest, induction of
DNA repair, induction of apoptosis, induction of
cell senescence, and the prohibition of cell metasta-
sis and angiogenesis (Fig. 7).61 The actions of these
many gene targets serve to inhibit five of the six hall-
mark features of cancer cells identified by Hanahan
and Weinberg in their seminal review of the sub-
ject.62 Thus, mutation and inactivation of p53 dis-
rupts these many tumor–suppressor qualities and
advances the neoplastic transformation of a cell.
Consistent with this, p53 is typically normal in BE
cells but frequently mutated in BE with high-grade
dysplasia and in EAC.63
One other feature of p53 should be noted here.
MDM2 is a ubiquitin ligase and an important
p53 target gene. MDM2 normally ubiquinates p53,
shunting it to the proteosome for degradation. In
cells with normal p53, induction of MDM2 acts to
feedback and limit p53 levels. However, when p53
is mutated, it cannot induce MDM2, and there-
fore levels of mutant p53 remain elevated. This is
why immunohistochemistry for p53 in BE tissues
is being studied as a marker for predicting disease
progression.63 Those tissues that have acquired a
mutant p53 will often have elevated p53 levels eas-
ily detected by immunohostochemistry. And those
cells with p53 mutations are at an advanced stage in
their transformation to cancer.
In summary, with regard to the question: is
there one transcription factor that shows a signif-
icant increase in the progression from BM to ade-
nocarcinoma? The answer to this is: it is a trick
question. Levels of the tumor suppressor (and tran-
scription factor) p53 are frequently increased with
progression to HGD and EAC, and may be a use-
ful marker predicting likely progression to adeno-
carcinoma. However, this is a mutated form that
is transcriptionally inactive. Loss of p53 function
confers many hallmark features for neoplasia, and
undoubtedly contributes to progression of BE cells
to EAC.
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